Merck’s Focus On ADCs Expands To Include Protein Degraders With C4

 
• By Joseph Haas

Deal snapshot: Viewing antibody-drug conjugates as a key to growing its cancer franchise beyond Keytruda, Merck & Co. will partner with C4 to develop protein degrader-antibody conjugates for cancer.

Merck makes move into degrader-antibody conjugates via pact with C4

More from Deals

More from Business